Shilpa Medicare secured historic approval for NorUDCA, the first-in-class NAFLD therapy, pioneering treatment access in India and globally.

• NorUDCA shows superior efficacy over placebo, significantly improving liver structure and function in NAFLD patients.
• NAFLD affects 25% of the global population, with 188 million cases in India alone, needing urgent medical solutions.
• Shilpa to launch NorUDCA tablets in India immediately, with plans for international regulatory submissions and global availability.